NorthWest Biotherapeutics Inc (NWBO)

[Astavakra]

Good catch Flipper.
I believe I heard Linda say at the last Marcum conference that initial patient uptake in the Direct trial is expected to be slow due to FDA. With a novel therapy, they like to see how the first patient tolerates and then slowly, initially, trickle in more patients. She explained that after initial logjam, enrollment will shoot up quickly.
I say this from my memory having been at the talk. If not exact, I believe that it is a close paraphrase to her remarks.
What I would really love an update on is whether they are approaching the end of that initial slow period, or, perhaps, have passed it.